Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23291979 | 0.96 | HDAC1 (0.64) | HDAC1HDAC6HDAC8CYP1A2CYP2D6 | |
| SCHEMBL23780442 | 0.79 | HDAC1 (0.69) | HDAC1HDAC6HDAC8CYP1A2CYP2D6 | |
| SCHEMBL23780428 | 0.79 | HDAC1 (0.48) | HDAC1HDAC6HDAC8CYP1A2CYP2D6 | |
| SCHEMBL23780440 | 0.79 | PPARA (0.49) | HDAC1HDAC6CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23780441 | 0.79 | PPARA (0.49) | HDAC1HDAC6CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23780446 | 0.77 | HDAC6 (0.70) | HDAC1HDAC6HDAC8CYP1A2CYP2D6 | |
| SCHEMBL23780447 | 0.77 | HDAC6 (0.70) | HDAC1HDAC6HDAC8CYP1A2CYP2D6 | |
| SCHEMBL19745104 | 0.76 | HDAC6 (1.00) | HDAC1HDAC6HDAC8HDAC4 | |
| SCHEMBL23780422 | 0.74 | PPARA (0.46) | HDAC1HDAC6HDAC8CYP1A2CYP2D6 | |
| SCHEMBL23780420 | 0.74 | PPARA (0.46) | HDAC1HDAC6HDAC8CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187712-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2025-01-07 | — | — | US | claimed |
| EP-3814343-B1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2023-01-11 | — | — | EP | claimed |
| US-12187712-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3814343-B1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3814343-B1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS INC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20210276991-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210276991-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187712-B2 | Cardiac sarcomere inhibitors | TNNI3, TNNT2, MYLK2 | HDAC1 203/4885HDAC6 233/4885HDAC8 647/4885 |
| US-20210276991-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, TNNT2, MYLK2 | HDAC1 203/4885HDAC6 233/4885HDAC8 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.